ResMed Inc. (CHESS) Company Profile (ASX:RMD)

About ResMed Inc. (CHESS) (ASX:RMD)

ResMed Inc. (CHESS) logoResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: N/A
  • Symbol: ASX:RMD
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: A$9.60
  • 200 Day Moving Avg: A$9.49
  • Trailing P/E Ratio: 41.25
  • P/E Growth: 2.42
  • Dividend Yield: 1.0%

Frequently Asked Questions for ResMed Inc. (CHESS) (ASX:RMD)

What is ResMed Inc. (CHESS)'s stock symbol?

ResMed Inc. (CHESS) trades on the ASX under the ticker symbol "RMD."

Who are some of ResMed Inc. (CHESS)'s key competitors?

Who are ResMed Inc. (CHESS)'s key executives?

ResMed Inc. (CHESS)'s management team includes the folowing people:

  • Rob Douglas, President, Chief Operating Officer
  • Michael Farrell, Chief Executive Officer, Director
  • Brett A. Sandercock, Chief Financial Officer
  • Jim Hollingshead Ph.D., President - Americas
  • Anne Reiser, President – Europe & Asia Pacific
  • David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary
  • Agnes Lee, Senior Director - Investor Relations
  • Peter C. Farrell Ph.D., Non-Executive Chairman of the Board
  • Ronald R. Taylor, Lead Independent Director
  • Carol J. Burt, Independent Director

MarketBeat Community Rating for ResMed Inc. (CHESS) (ASX RMD)
Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  66
MarketBeat's community ratings are surveys of what our community members think about ResMed Inc. (CHESS) and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ResMed Inc. (CHESS) (ASX:RMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ResMed Inc. (CHESS) (ASX:RMD)
No equities research coverage for this company has been tracked by


Earnings History for ResMed Inc. (CHESS) (ASX:RMD)
No earnings announcements for this company have been tracked by


Earnings Estimates for ResMed Inc. (CHESS) (ASX:RMD)

No earnings estimates for this company have been tracked by


Dividend History for ResMed Inc. (CHESS) (ASX:RMD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ResMed Inc. (CHESS) (ASX:RMD)
No insider trades for this company have been tracked by


Headline Trends for ResMed Inc. (CHESS) (ASX:RMD)
Latest Headlines for ResMed Inc. (CHESS) (ASX:RMD)
DateHeadline logo2 healthcare shares to consider if you're new to investing - Motley Fool Australia - September 19 at 7:14 AM logoETFs with exposure to ResMed, Inc. : August 25, 2017 - August 26 at 8:54 AM logoSee what the IHS Markit Score report has to say about ResMed Inc. - August 13 at 5:54 AM logoResMed, Inc. :RMD-AU: Earnings Analysis: Q4, 2017 By the Numbers : August 9, 2017 - August 10 at 7:29 AM logoResMed, Inc. :RMD-AU: Earnings Analysis: 2017 By the Numbers : August 8, 2017 - August 9 at 6:57 AM logo3 family-run ASX companies for your investing watchlist - Motley Fool Australia - August 4 at 7:39 AM logo5 reasons to buy ResMed Inc (CHESS) shares today - Motley Fool Australia - August 4 at 7:39 AM logoResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track - August 2 at 3:57 PM logoWant quarterly dividends? Buy these 4 stocks - July 11 at 7:08 AM logoWhy the Compumedics Limited share price fell 19% today - Motley Fool Australia - July 8 at 2:05 PM logoWhy Is ResMed (RMD) Down 3.8% Since the Last Earnings Report? - May 31 at 12:47 PM logoAttention: These 3 healthcare shares are powering the S&P/ASX 200 to new highs - Motley Fool Australia - May 29 at 6:32 PM logo2 healthcare shares with dividend yields over 6.5% - Motley Fool Australia - May 29 at 12:59 AM logoIs Your Portfolio Diversified? - Motley Fool Australia - May 29 at 12:59 AM logoRecord profits: Is Fisher & Paykel Healthcare Corp Ltd still a buy? - Motley Fool Australia - May 23 at 6:58 PM logoBig Data Yields Big Insights for Treatment of Central Sleep Apnea - May 22 at 9:19 AM logoStatement by ResMed on Plans to Renew Its Patent Infringement Case Against Fisher & Paykel - May 17 at 5:31 AM logoIntroducing the Softest CPAP Mask from ResMed - May 16 at 9:31 AM logoETFs with exposure to ResMed, Inc. : May 11, 2017 - May 11 at 8:02 PM logoResMed, Inc. :RMD-AU: Earnings Analysis: Q3, 2017 By the Numbers : May 8, 2017 - May 9 at 10:46 AM logoAcquisitions Help Drive ResMed's Revenue 13% Higher - May 1 at 10:13 AM logoResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates - April 28 at 3:37 PM logoWhy ResMed Inc (CHESS) still offers investors big potential - April 27 at 8:00 PM logoHere are 3 shares on the S&P/ASX 100 I would buy today - Motley Fool Australia - April 10 at 7:06 PM logoHere are 3 quality shares on the S&P/ASX 100 that I would buy today - April 4 at 5:11 AM logoASX preview on Thursday: 9 shares you need to watch today - Motley Fool Australia - March 9 at 7:33 PM logoASX 200 rebounds on Tuesday: 9 shares you should have been watching - January 24 at 12:55 AM logoResMed Q2 profit down but revenue up - January 24 at 12:55 AM logoBlueScope, ResMed news boosts share market - January 24 at 12:55 AM logoWhy it’s time to wake up to ResMed Inc.’s (CHESS) potential - January 23 at 7:54 PM logoWhy the Australian Dollar is skyrocketing toward US75 cents - Motley Fool Australia - January 13 at 1:18 AM logoResMed and Dr. Oz Form SleepScore Labs for Sleep Disorders - January 9 at 8:49 AM logoDebt Binge: Is this why the CSL Limited share price is plunging? - Motley Fool Australia - December 12 at 9:27 AM logo3 ASX stocks to buy now to get rich later - October 20 at 8:33 AM logo4 growth shares I can’t help but love - October 13 at 10:48 AM logo4 ASX shares to help you to an early retirement - September 29 at 12:13 PM logo3 growth shares I’d buy with $10,000 today - September 16 at 6:50 PM logo3 blue-chip shares that won’t let you down - September 10 at 6:17 PM logoResMed (RMD) Stock Slides, Jefferies Downgrades to 'Underperform' - August 23 at 7:18 PM logoLook at Medical Product Earnings on Jul 28: BSX, RMD & More - July 27 at 6:59 AM logoThe easy way to start building a $1 million share portfolio in FY 2017 - July 20 at 10:00 AM logoResMed books mixed third-quarter results - April 26 at 8:45 PM logoResMed Q3 revenue up 7 pct - April 26 at 7:42 PM logoResMed: Strong Cash Balance, Product Portfolio Drive Growth - April 8 at 2:50 PM logoResMed (RMD) Stock Gets 'Underweight' Rating at Barclays - April 7 at 9:17 AM logoResMed (RMD) Announces Completion of Inova Labs Acquisition - February 4 at 2:36 PM logoWhy AGL Energy Ltd & Fisher & Paykel Healthcare Corp Ltd could offer growth & income - February 3 at 7:19 PM logoResMed Inc. (RMD) Jumped To A 6-Week High On Strong Q2 Earnings - January 25 at 1:15 PM logoWhy ResMed Inc's Stock Is Up Big Today - January 22 at 12:17 PM logoResmed lifts 2Q revenue 7% to $US454.5m - January 21 at 5:50 PM


Social activity is not available for this stock.
This page was last updated on 9/20/2017 by Staff